Amprologix
A biotechnology and synthetic biology company developing antibiotics to treat drug-resistant bacterial infections.
All edits
' fill='white' fill-rule='nonzero'%3e%3cpath d='M52 12c-22.048 0-40 17.952-40 40 0 10.848 4.48 21.376 12.288 28.864 7.008 6.752 16.096 10.592 25.792 11.04.48.032.992.096 1.472.096H52c10.336 0 20.128-3.904 27.616-11.04C87.616 73.312 92 63.04 92 52c0-22.048-17.952-40-40-40zm26.912 65.056c-1.472-5.216-8.448-8.032-13.696-10.112l-1.792-.736C60 64.8 60 63.488 60 61.6c0-1.344.672-3.264 1.888-4.416 3.104-2.72 4.736-6.464 4.736-10.816 0-8.8-6.144-15.168-14.624-15.168-8.448 0-14.336 6.24-14.336 15.168 0 4.544 1.536 8.192 4.512 10.816 1.248 1.12 1.792 3.072 1.792 4.416 0 1.344 0 3.008-4.16 4.704-5.12 2.112-11.904 4.992-15.008 10.432C18.688 69.984 15.2 61.12 15.2 52c0-20.288 16.512-36.8 36.8-36.8 20.288 0 36.8 16.512 36.8 36.8 0 9.408-3.52 18.208-9.888 25.056z'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Amprologix is a University of Plymouth spin-out . Amprologix was established to develop the work of Professor Mathew Upton, professor of Medical Microbiology. The company aims to introduce new classes of antibiotics to help tackle the threat of antimicrobial resistance. Amprologix has secured industry involvement through a partnership with Ingenza. Ingenza's biologics manufacturing platform will be used to enable viable production at scale.
Epidermicins are a new class of antibiotics capable of tackling MRSA and related superbugs at very low doses. The first product from the company is expected to be a cream containing epidermicin, which can rapidly kill harmful bacteria, including MRSA, Streptococcus and Entercoccus at very low doses.
Epidermicins are a new class of antibiotics capable of tackling MRSA and related superbugs at very low doses. The first product from the company is expected to be a cream containing epidermicin, which can rapidly kill harmful bacteria, including MRSA, Streptococcus and Entercoccus at very low doses.
Amprologix
A biotechnology and synthetic biology company developing antibiotics to treat drug-resistant bacterial infections.
Amprologix was awarded a £1.2 million contract from the UK Department of HealthHealth and Social Care to accelerate the development and scale up its lead antibiotic candidate, Epidermicin NI01. The funding, administered by Innovate UK, is intended to advance Epidermicin NI01 which is part of a new family of epidermicin-based antibiotics expected to be ready for Phase I clinical trials by early 2021. With this funding, Amprologix will optimise the formulation of Epidermicin NI01 as a cream to decolonise the nasal cavity of MRSA. A preclinical toxicology evaluation will be conducted.
Amprologix was awarded a £1.2 million contract from the UK Department of HealthHealth and Social Care to accelerate the development and scale up its lead antibiotic candidate, Epidermicin NI01. The funding, administered by Innovate UK, is intended to advance Epidermicin NI01 which is part of a new family of epidermicin-based antibiotics expected to be ready for Phase I clinical trials by early 2021. With this funding, Amprologix will optimise the formulation of Epidermicin NI01 as a cream to decolonise the nasal cavity of MRSA. A preclinical toxicology evaluation will be conducted.
Amprologix was awarded a £1.2 million contract from the UK Department of Health and Social Care to accelerate the development and scale up its lead antibiotic candidate, Epidermicin NI01. The funding, administered by Innovate UKInnovate UK, is intended to advance Epidermicin NI01 which is part of a new family of epidermicin-based antibiotics expected to be ready for Phase I clinical trials by early 2021. With this funding, Amprologix will optimise the formulation of Epidermicin NI01 as a cream to decolonise the nasal cavity of MRSA. A preclinical toxicology evaluation will be conducted.
Amprologix is a University of PlymouthPlymouth spin-out . Amprologix was established to develop the work of Professor Mathew Upton, professor of Medical Microbiology. The company aims to introduce new classes of antibiotics to help tackle the threat of antimicrobial resistance. Amprologix has secured industry involvement through a partnership with Ingenza. Ingenza's biologics manufacturing platform will be used to enable viable production at scale.
Amprologix is a University of Plymouth spin-out . Amprologix was established to develop the work of Professor Mathew Upton, professor of Medical MicrobiologyMedical Microbiology. The company aims to introduce new classes of antibiotics to help tackle the threat of antimicrobial resistance. Amprologix has secured industry involvement through a partnership with Ingenza. Ingenza's biologics manufacturing platform will be used to enable viable production at scale.
Amprologix is a UniversityUniversity of Plymouth spin-out . Amprologix was established to develop the work of Professor Mathew Upton, professor of Medical Microbiology. The company aims to introduce new classes of antibiotics to help tackle the threat of antimicrobial resistance. Amprologix has secured industry involvement through a partnership with Ingenza. Ingenza's biologics manufacturing platform will be used to enable viable production at scale.
Find more companies like Amprologix
